CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Aurobindo Pharma Ltd., resolving patent litigation brought in response to Aurobindo Pharma's abbreviated new
- Urges Shareholders to Vote "FOR" the Ironwood Director Nominees on the WHITE Proxy Card - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that it filed definitive proxy materials with the Securities and Exchange
- Separation designed to unlock value, increase operational performance and strategic flexibility, and tailor capital structure for each business - - Separation expected to result in two independent, publicly traded companies - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.
– First quarter revenue increased 33% year-over-year to $69 million , driven primarily by LINZESS ® (linaclotide) U.S. net sales of $159 million and commercial margin of 63% – – IW-3718 Phase III program expected to initiate in the third quarter of 2018 – – Phase II sGC programs, praliciguat and
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 17, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, May 1, 2018 . Individuals interested in participating in the call
- Advises Shareholders That No Action Is Required at This Time - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that it has received notice from Sarissa Capital Management LP ("Sarissa") that it intends to nominate
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in March: 2018 Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 11:20 a.m.
- Generated 2017 revenue of $298 million , driven primarily by LINZESS ® (linaclotide) U.S. net sales of $701 million and expansion of LINZESS commercial margin to 61% - - On track to advance key pipeline candidates in 2018, including Phase III trials for IW-3718 and LINZESS and Phase II trials for
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2017 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2018 .
You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.
Delicious
Digg
Facebook
LinkedIn
Twitter
